NCT05048862 The Neuroimage Study of the Neuromuscular Disorders.
| NCT ID | NCT05048862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Neuromuscular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-08-01 |
| Primary Completion | 2031-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-08-01 with a primary completion date of 2031-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The neuromuscular disorders could be briefly divided to neuropathy, myopathy, motor neuron disease, and neuromuscular junction disorder. In the past, the evaluation of the neuromuscular disorders depended on several ways (ex. electrodiagnostic studies and biopsy) to evaluate the pathophysiology and the pathological change. However, due to the issue of resolution, few image studies were available to evaluate the structure for clinical practice. With the growing techniques, there are two ways to see the nerve and muscle in vivo, the magnetic resonance imaging (MRI) and the ultrasonography. The availability of the machine, the high cost, inability to change the position for dynamic views of the nerves, and the relative invasion considering the large energy penetrating the patient might limit the clinical use of MRI. The nerve ultrasonography is a safe and easily available technique. The development of high-frequency transducers has led to an improvement in the resolution of ultrasonography and enables the exploration of peripheral nerve and muscle structural changes. In additional to evaluate the morphological changes, ultrasonography has been used extensively for the vessel status assessment through duplex ultrasound. In present study, we will apply variable approaches, including to muscle, nerve, and skin biopsy, electrophysiological study, quantitative sensory testing, autonomic functional tests, pain evoked potentials, MRI, and ultrasonography to integrally investigate the different aspects of neuromuscular disorders. The results of the study will provide integrated insights of (1) the neurophysiology of nerve and vessels and (2) pathogenesis of different neuromuscular disorders.
Eligibility Criteria
Inclusion Criteria (Neuromuscular group): * been diagnosed as neuromuscular disorders by the neurologist * at least 20-year-old Inclusion Criteria (Normal group): * no past history of neurological disorders. * The neurological examination performed by the board neurologist must be normal * at least 20-year-old Exclusion Criteria (Neuromuscular and normal group): * Patients who are unable to read the questionnaire, fail to accept all the examinations, and refuse to provide inform consent
Contact & Investigator
Hsueh-Wen Hsueh, MD, MMS
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT05048862 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Neuromuscular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05048862 currently recruiting?
Yes, NCT05048862 is actively recruiting participants. Contact the research team at 102194@ntuh.gov.tw for enrollment information.
Where is the NCT05048862 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT05048862 clinical trial?
NCT05048862 is sponsored by National Taiwan University Hospital. The principal investigator is Hsueh-Wen Hsueh, MD, MMS at National Taiwan University Hospital. The trial plans to enroll 500 participants.